Adults with dry age-related macular degeneration resulting in geographic atrophy are invited to participate in a research study at UVa
15723
A phase 2, multi-centre, randomised, double-masked, placebo controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Ophthalmology
Shildkrot Yevgeniy,
UVa is conducting a research study on geographic atrophy secondary to dry age-related macular degeneration. The purpose of this 27 month study is to evaluate the safety of an investigational study drug, called GSK933776. You may qualify for this study if you: 1. Are at least 55 years of age 2. Have geographic atrophy secondary to dry AMD in the study eye 3. Visual acuity better than 20/200 in the study eye 4. No history of wet AMD in either eye What is involved? After completing a screening and observation period, eligible participants will be randomized (like the flip of a coin) to one of three study drug groups (2 groups receive the study drug and 1 group receives placebo). All participants will receive 18 intravenous infusions (once per month for 18 consecutive months) of their assigned study drug group. For more information about this study: Please contact the Study Coordinator, Kristina Holbrook, at (434) 243-2852 or klh7v@virginia.edu or visit http://www.clinicaltrials.gov/ct2/show/NCT01342926?term=gsk+geographic+atrophy&rank=1 Study Title: IRB-HSR # 15723: A phase 2, multi-centre, randomised, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) The principal investigator is Paul A. Yates, MD, PhD.
Adult
Macular Degeneration
Ophthalmology
Ill
No Compensation
Kristina Holbrook
klh7v@virginia.edu
4342432852
